Q3-osavuosiraportti
2 päivää sitten‧40 min
2,50 SEK/osake
Viimeisin osinko
1,51 %
Tuotto/v
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
6 133
Myynti
Määrä
6 717
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 63 | - | - | ||
| 35 | - | - | ||
| 46 | - | - | ||
| 46 | - | - | ||
| 91 | - | - |
Ylin
167,4VWAP
Alin
161VaihtoMäärä
8,2 49 689
VWAP
Ylin
167,4Alin
161VaihtoMäärä
8,2 49 689
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 5.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 6.11. | |
| 2025 Q2-osavuosiraportti | 18.7. | |
| 2024 Yhtiökokous | 6.5. | |
| 2025 Q1-osavuosiraportti | 29.4. | |
| 2024 Q4-osavuosiraportti | 6.2. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3.11.Report on Thursday, the company has a good track record and I believe they continue to deliver stable figures. - Don't know, but maybe they've released a new software version (no blockbuster, but still feels good) - 2026 Q1 (will probably be Q2) they will release an application for bone marrow analysis. Does anyone have an educated guess as to what this could entail... an additional 10% on revenue after a few quarters..? - It would be nice if they could come up with an acquisition, preferably to broaden the business somewhat·2 päivää sittenToday's report: - A bit weaker... - Revenue decreases slightly; increases slightly organically - The margin is approximately like the comparison quarter - The bone marrow analysis project seems to be on track - New software for hematology seems ready, installed at a test customer - We'll see how the market receives this report They need to get growth going again: - Bone marrow analysis will surely contribute somewhat 2026 H2 - Previously they have talked about a small broadening, e.g. towards pathology - Why not broaden the business to something related to what they already do. Perhaps an acquisition? BR is strong!
·6.2.Cellavision released its quarterly report for Q4 2024 today. I have released a written commentary with numbers, graphs and explanatory text: https://murgata.se/cellavision-rapportkommentar-q4-2024/ And I have released this film that should be seen as a complement to the written report. 👇 https://www.youtube.com/shorts/YK7StWx-Zxo
5.11.2023 · Muokattu5.11.2023 · MuokattuLike the company due to its healthy gross margin and solid historical topline growth. Despits negative revenue growth during Q4-22 to Q2-23, I'm not all to worried about its ability to continue delivering topline growth. What makes me hesitant though, is the valuation and their operating leverage. Regarding operating leverage, since they're selling through distributors which are paid by commission, I expect their selling expenses growing along with revenue growth. Thus, I don't see a potential scalability/increased profit margin from this income statement row. R&D and general administrative expenses as a share of revenue does not trend down despite growing their revenues. Seeing R&D spend growing along with revenue, I find positive though as I considered that a necessity in order to stay relevant and continuing to grow/introduce new products. However, I would definitely preferred so see G&A growing slowing than revenue. So for me, this is basically a topline growth story which I would enter when I find valuation to be attractive (defining an attractive valuation level is highly subjective though). I would've found this company much more attractive, if they were having their own sales administration, unlocking a much clearer potential for expanding operating margins. Would very much appreciated being proven wrong by anyone in this community as I like CEVI's attractive topline growth story and fat gross margins.
·7.2.2024Turnover rose 31.7 percent to SEK 200.6 million (152.3). The organic sales growth was 29 percent (-17). It is the highest turnover so far during a quarter for the company. "All product groups and regions contributed to growth during the quarter. Globally, market penetration within large laboratories increased to 27 percent (26)," says CEO Simon Østergaard.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
2 päivää sitten‧40 min
2,50 SEK/osake
Viimeisin osinko
1,51 %
Tuotto/v
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3.11.Report on Thursday, the company has a good track record and I believe they continue to deliver stable figures. - Don't know, but maybe they've released a new software version (no blockbuster, but still feels good) - 2026 Q1 (will probably be Q2) they will release an application for bone marrow analysis. Does anyone have an educated guess as to what this could entail... an additional 10% on revenue after a few quarters..? - It would be nice if they could come up with an acquisition, preferably to broaden the business somewhat·2 päivää sittenToday's report: - A bit weaker... - Revenue decreases slightly; increases slightly organically - The margin is approximately like the comparison quarter - The bone marrow analysis project seems to be on track - New software for hematology seems ready, installed at a test customer - We'll see how the market receives this report They need to get growth going again: - Bone marrow analysis will surely contribute somewhat 2026 H2 - Previously they have talked about a small broadening, e.g. towards pathology - Why not broaden the business to something related to what they already do. Perhaps an acquisition? BR is strong!
- ·6.2.Cellavision released its quarterly report for Q4 2024 today. I have released a written commentary with numbers, graphs and explanatory text: https://murgata.se/cellavision-rapportkommentar-q4-2024/ And I have released this film that should be seen as a complement to the written report. 👇 https://www.youtube.com/shorts/YK7StWx-Zxo
- 5.11.2023 · Muokattu5.11.2023 · MuokattuLike the company due to its healthy gross margin and solid historical topline growth. Despits negative revenue growth during Q4-22 to Q2-23, I'm not all to worried about its ability to continue delivering topline growth. What makes me hesitant though, is the valuation and their operating leverage. Regarding operating leverage, since they're selling through distributors which are paid by commission, I expect their selling expenses growing along with revenue growth. Thus, I don't see a potential scalability/increased profit margin from this income statement row. R&D and general administrative expenses as a share of revenue does not trend down despite growing their revenues. Seeing R&D spend growing along with revenue, I find positive though as I considered that a necessity in order to stay relevant and continuing to grow/introduce new products. However, I would definitely preferred so see G&A growing slowing than revenue. So for me, this is basically a topline growth story which I would enter when I find valuation to be attractive (defining an attractive valuation level is highly subjective though). I would've found this company much more attractive, if they were having their own sales administration, unlocking a much clearer potential for expanding operating margins. Would very much appreciated being proven wrong by anyone in this community as I like CEVI's attractive topline growth story and fat gross margins.·7.2.2024Turnover rose 31.7 percent to SEK 200.6 million (152.3). The organic sales growth was 29 percent (-17). It is the highest turnover so far during a quarter for the company. "All product groups and regions contributed to growth during the quarter. Globally, market penetration within large laboratories increased to 27 percent (26)," says CEO Simon Østergaard.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
6 133
Myynti
Määrä
6 717
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 63 | - | - | ||
| 35 | - | - | ||
| 46 | - | - | ||
| 46 | - | - | ||
| 91 | - | - |
Ylin
167,4VWAP
Alin
161VaihtoMäärä
8,2 49 689
VWAP
Ylin
167,4Alin
161VaihtoMäärä
8,2 49 689
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 5.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 6.11. | |
| 2025 Q2-osavuosiraportti | 18.7. | |
| 2024 Yhtiökokous | 6.5. | |
| 2025 Q1-osavuosiraportti | 29.4. | |
| 2024 Q4-osavuosiraportti | 6.2. |
Datan lähde: Millistream, Quartr
Q3-osavuosiraportti
2 päivää sitten‧40 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 5.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 6.11. | |
| 2025 Q2-osavuosiraportti | 18.7. | |
| 2024 Yhtiökokous | 6.5. | |
| 2025 Q1-osavuosiraportti | 29.4. | |
| 2024 Q4-osavuosiraportti | 6.2. |
Datan lähde: Millistream, Quartr
2,50 SEK/osake
Viimeisin osinko
1,51 %
Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3.11.Report on Thursday, the company has a good track record and I believe they continue to deliver stable figures. - Don't know, but maybe they've released a new software version (no blockbuster, but still feels good) - 2026 Q1 (will probably be Q2) they will release an application for bone marrow analysis. Does anyone have an educated guess as to what this could entail... an additional 10% on revenue after a few quarters..? - It would be nice if they could come up with an acquisition, preferably to broaden the business somewhat·2 päivää sittenToday's report: - A bit weaker... - Revenue decreases slightly; increases slightly organically - The margin is approximately like the comparison quarter - The bone marrow analysis project seems to be on track - New software for hematology seems ready, installed at a test customer - We'll see how the market receives this report They need to get growth going again: - Bone marrow analysis will surely contribute somewhat 2026 H2 - Previously they have talked about a small broadening, e.g. towards pathology - Why not broaden the business to something related to what they already do. Perhaps an acquisition? BR is strong!
- ·6.2.Cellavision released its quarterly report for Q4 2024 today. I have released a written commentary with numbers, graphs and explanatory text: https://murgata.se/cellavision-rapportkommentar-q4-2024/ And I have released this film that should be seen as a complement to the written report. 👇 https://www.youtube.com/shorts/YK7StWx-Zxo
- 5.11.2023 · Muokattu5.11.2023 · MuokattuLike the company due to its healthy gross margin and solid historical topline growth. Despits negative revenue growth during Q4-22 to Q2-23, I'm not all to worried about its ability to continue delivering topline growth. What makes me hesitant though, is the valuation and their operating leverage. Regarding operating leverage, since they're selling through distributors which are paid by commission, I expect their selling expenses growing along with revenue growth. Thus, I don't see a potential scalability/increased profit margin from this income statement row. R&D and general administrative expenses as a share of revenue does not trend down despite growing their revenues. Seeing R&D spend growing along with revenue, I find positive though as I considered that a necessity in order to stay relevant and continuing to grow/introduce new products. However, I would definitely preferred so see G&A growing slowing than revenue. So for me, this is basically a topline growth story which I would enter when I find valuation to be attractive (defining an attractive valuation level is highly subjective though). I would've found this company much more attractive, if they were having their own sales administration, unlocking a much clearer potential for expanding operating margins. Would very much appreciated being proven wrong by anyone in this community as I like CEVI's attractive topline growth story and fat gross margins.·7.2.2024Turnover rose 31.7 percent to SEK 200.6 million (152.3). The organic sales growth was 29 percent (-17). It is the highest turnover so far during a quarter for the company. "All product groups and regions contributed to growth during the quarter. Globally, market penetration within large laboratories increased to 27 percent (26)," says CEO Simon Østergaard.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
6 133
Myynti
Määrä
6 717
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 63 | - | - | ||
| 35 | - | - | ||
| 46 | - | - | ||
| 46 | - | - | ||
| 91 | - | - |
Ylin
167,4VWAP
Alin
161VaihtoMäärä
8,2 49 689
VWAP
Ylin
167,4Alin
161VaihtoMäärä
8,2 49 689
Välittäjätilasto
Dataa ei löytynyt